RBC Capital lowered the firm’s price target on Illumina (ILMN) to $128 from $247 but keeps an Outperform rating on the shares. The company’s ...
In a report released yesterday, Conor McNamara from RBC Capital maintained a Buy rating on Illumina (ILMN – Research Report), with a price ...
Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, has been named for the sixth year in a row to the Dow Jones Best-in-Class World Index and the Dow ...